CGC vs. USNA, CRON, BTMD, GERN, WRBY, TARO, EQRX, GMTX, INBX, and OMI
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include USANA Health Sciences (USNA), Cronos Group (CRON), biote (BTMD), Geron (GERN), Warby Parker (WRBY), Taro Pharmaceutical Industries (TARO), EQRx (EQRX), Gemini Therapeutics (GMTX), Inhibrx (INBX), and Owens & Minor (OMI). These companies are all part of the "medical" sector.
Canopy Growth vs.
Canopy Growth (NASDAQ:CGC) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
USANA Health Sciences has a net margin of 6.94% compared to Canopy Growth's net margin of -721.40%. USANA Health Sciences' return on equity of 16.92% beat Canopy Growth's return on equity.
Canopy Growth presently has a consensus price target of $4.53, indicating a potential upside of 143.30%. USANA Health Sciences has a consensus price target of $52.75, indicating a potential downside of 14.51%. Given Canopy Growth's stronger consensus rating and higher probable upside, research analysts plainly believe Canopy Growth is more favorable than USANA Health Sciences.
In the previous week, Canopy Growth's average media sentiment score of 1.73 beat USANA Health Sciences' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.
Canopy Growth has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
USANA Health Sciences received 359 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 60.16% of users gave USANA Health Sciences an outperform vote while only 21.28% of users gave Canopy Growth an outperform vote.
15.8% of Canopy Growth shares are owned by institutional investors. Comparatively, 52.6% of USANA Health Sciences shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Comparatively, 0.4% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
USANA Health Sciences beats Canopy Growth on 11 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
